Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...

In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...

Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the ...

Emerson has been at the helm of Lykos since 2014 and has been involved in the development of its MDMA-based midomafetamine therapy for post-traumatic stress disorder (PTSD) for more than 20 years.

Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...

Lykos Therapeutics is slashing around 75% of its staff following the FDA's decision not to approve its MDMA-assisted therapy for post-traumatic stress disorder (PTSD) last week, with founder Rick ...

The FDA recently declined to approve MDMA-assisted therapy for PTSD, but experts said there are many other treatments on the ...

T he Food and Drug Administration (FDA) declined on Friday to approve MDMA-assisted psychotherapy as a treatment for ...

“As someone who’s spoken to people who have had their lives saved due to MDMA-therapy, the FDA’s decision to deny Lykos’ application comes as a great disappointment,” said Kat ...

Lykos described that request as "deeply disappointing," saying it hoped existing evidence could resolve the agency's concerns. The advisory committee overwhelmingly concluded that MDMA's ...

Recommended Reading In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD The CEO of Lykos Therapeutics will step down after the company’s efforts to win a milestone approval for ...

Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug ...